ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by US Bancorp DE

US Bancorp DE grew its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 11,951.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,680 shares of the company’s stock after acquiring an additional 18,525 shares during the period. US Bancorp DE’s holdings in ARS Pharmaceuticals were worth $271,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of SPRY. nVerses Capital LLC acquired a new position in ARS Pharmaceuticals in the third quarter worth about $30,000. Russell Investments Group Ltd. bought a new position in ARS Pharmaceuticals in the first quarter worth about $60,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock worth $63,000 after acquiring an additional 4,472 shares during the last quarter. Principal Financial Group Inc. bought a new position in ARS Pharmaceuticals in the second quarter worth about $87,000. Finally, Paloma Partners Management Co bought a new position in ARS Pharmaceuticals in the first quarter worth about $103,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, COO Brian Dorsey sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $15.00, for a total transaction of $750,000.00. Following the sale, the chief operating officer now owns 6,024 shares of the company’s stock, valued at $90,360. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other ARS Pharmaceuticals news, COO Brian Dorsey sold 50,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $15.00, for a total value of $750,000.00. Following the transaction, the chief operating officer now owns 6,024 shares in the company, valued at approximately $90,360. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Richard E. Lowenthal sold 100,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $12.93, for a total transaction of $1,293,000.00. Following the completion of the transaction, the chief executive officer now owns 1,398,499 shares in the company, valued at approximately $18,082,592.07. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,584,351 shares of company stock valued at $24,152,378 over the last quarter. Corporate insiders own 40.10% of the company’s stock.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ:SPRY opened at $14.08 on Thursday. ARS Pharmaceuticals, Inc. has a 12 month low of $4.01 and a 12 month high of $18.51. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -29.96 and a beta of 0.90. The stock’s 50 day moving average price is $14.53 and its 200 day moving average price is $11.65.

Analysts Set New Price Targets

A number of brokerages have issued reports on SPRY. Raymond James raised shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $18.00 to $22.00 in a report on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $30.00 price target on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Leerink Partners lifted their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, September 20th. Finally, William Blair raised ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $24.00.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.